Yoga app for patients receiving chest radiation and their family caregivers
Official title: Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
Run by M.D. Anderson Cancer Center · NCT06919874 · Data updated 2026-11-12
This test tries a mobile app that delivers an unsupervised yoga program for people getting thoracic radiation and their family caregivers to see if it is usable and acceptable.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | May 14, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | September 25, 2026 |
| Trial ID | NCT06919874 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with non-small cell lung or esophageal cancer scheduled to receive at least 24 fractions of thoracic radiotherapy, with ECOG performance status <2, an English-speaking family caregiver willing to join, and regular access to high-speed internet are ideal candidates.
✕Probably not a fit
People with cognitive deficits that prevent completing questionnaires, medical contraindications to exercise, those who were regularly practicing yoga in the prior year, or those without English ability or reliable internet are unlikely to benefit from this app-based program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project develops and tests an app-based dyadic yoga program delivered on iOS and Android for patients undergoing thoracic radiotherapy and their family caregivers. In part 1, investigators will do usability testing with 10 patient-caregiver dyads to finalize the working prototypes and identify navigation or functionality problems. In part 2, they will run a single-arm feasibility pilot with 20 new dyads measuring consent and retention rates, adherence, usability, and acceptability, and will collect pre/post measures of objective physical function and self-reported quality of life. Semi-structured interviews will provide qualitative feedback on participants' experiences using the app and participating in the program.
Why it matters
Potential benefit: If successful, the app could provide an accessible way for patients and caregivers to do guided yoga at home during thoracic radiation, potentially improving symptoms and quality of life.
How similar studies have gone: In-person yoga programs for cancer patients and caregivers have shown quality-of-life benefits, but app-based, dyadic delivery during thoracic radiotherapy is largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Be diagnosed with a non-small cell lung cancer or esophageal cancer and going to receive at least 24 fractions thoracic RT 2. Have an ECOG performance status of \<2 3. Have a family caregiver (e.g., spouse, sibling, adult child) willing to participate Both patient and caregiver must meet all the following criteria: 1. Be \>18 years old 2. Be able to read and speak English 3. Be able to provide informed consent 4. Have regular (self-defined) access to Wi-Fi/High speed internet access Exclusion Criteria: 1. Experiences cognitive deficits that would impede the completion of self-report instruments as deemed by their attending oncologist per medical notes and/or patient not being oriented to time, place and person. 2. Regularly (self-defined) participants in a yoga program in the year prior to diagnosis Participants who participated in part 1 are ineligible to participate in part 2 of this protocol.
Where it's running
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Kathrin Milbury, MA,PHD — M.D. Anderson Cancer Center
- Study coordinator: Kathrin Milbury, MA,PHD
- Email: kmilbury@mdanderson.org
- Phone: (713) 745-2868
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.